Re: AACR

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: AACR

in response to

Re: AACR

tada

posted on Apr 01, 2019 05:58PM

"BDAZ - What is ZEN-3791? I don't remember ever hearing about that in the past."

It sounds like ZEN-3694 is metabolized to ZEN-3791, the latter of which is the "active" metabolite. I think the term for this is pro-drug, in which ZEN-3694 needs to be converted to a different form in the cell to become the active molecule. First I've heard of that for ZEN-3694.